Table 1.
Patient characteristics.
| Characteristic | CDK4/6is + ET, n = 2249 | Everolimus + ET, n = 1027 | Alpelisib + ET, n = 49 | |||||
|---|---|---|---|---|---|---|---|---|
| IDC, n = 1834 (81%) | ILC, n = 336 (15%) | Mixed, n = 79 (4%) | IDC, n = 843 (82%) | ILC, n = 141 (14%) | Mixed, n = 43 (4%) | IDC, n = 40 (82%) | ILC, n = 9 (18%) | |
| Age (years), median | 49 | 54 | 57 | 48 | 53 | 48 | 51 | 52 |
| Race, n (%) | ||||||||
| White | 1375 (75) | 269 (80) | 59 (75) | 613 (73) | 114 (81) | 35 (81) | 37 (93) | 7 (78) |
| Hispanic | 147 (8) | 34 (10) | 10 (13) | 87 (10) | 13 (9) | 5 (12) | 1 (3) | 1 (11) |
| Black | 165 (9) | 17 (5) | 5 (6) | 82 (10) | 5 (4) | 2 (5) | 2 (5) | 0 |
| Others | 147 (8) | 16 (5) | 5 (6) | 63 (8) | 9 (6) | 1 (2) | 0 | 1 (11) |
| ILC subtype, n (%) | ||||||||
| Classic | 318 (95) | 130 (92) | 9 (100) | |||||
| Pleomorphic | 18 (5) | 11 (8) | 0 | |||||
| Menopausal status, n (%) | ||||||||
| Pre | 1064 (58) | 148 (44) | 27 (35) | 464 (55) | 59 (42) | 23 (54) | 19 (48) | 4 (44) |
| Post | 770 (42) | 188 (56) | 52 (66) | 379 (45) | 82 (58) | 20 (47) | 21 (53) | 5 (56) |
| Estrogen receptor, n (%) | ||||||||
| Positive | 1779 (97) | 333 (99) | 77 (98) | 778 (92) | 138 (98) | 42 (98) | 37 (93) | 9 (100) |
| Negative | 55 (3) | 3 (1) | 2 (3) | 64 (8) | 3 (2) | 1 (2) | 3 (8) | 0 |
| Progesterone receptor, n (%) | ||||||||
| Positive | 1577 (86) | 285 (85) | 67 (85) | 655 (78) | 120 (85) | 37 (86) | 35 (88) | 9 (100) |
| Negative | 257 (14) | 51 (15) | 9 (11) | 187 (22) | 20 (14) | 6 (14) | 5 (13) | 0 |
CDK4/6is cyclin-dependent kinase 4 and 6 inhibitors, ET endocrine therapy, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, mixed, mixed invasive ductal and lobular carcinoma.
Others include Asian and Native American.